Recent News

• 12.23.2025 - Organogenesis Announces Initiation of Biologics License Application for ReNu®
• 12.15.2025 - Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
• 11.06.2025 - Organogenesis Holdings Inc. Third Quarter of Fiscal Year 2025 Earnings Conference Call
• 11.06.2025 - Organogenesis Holdings Inc. Third Quarter of Fiscal Year 2025 Earnings Conference Call
• 11.06.2025 - Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
• 11.03.2025 - Organogenesis Applauds CMS’s Significant Step In Payment Reform
• 10.31.2025 - Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 10.01.2025 - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
• 10.01.2025 - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
• 10.01.2025 - Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

Recent Filings

• 12.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 144 Report of proposed sale of securities
• 11.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 144 Report of proposed sale of securities
• 11.24.2025 - 144 Report of proposed sale of securities
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership